Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma — Stella

Home/Glioblastoma/

View on ClinicalTrials.gov

Recruiting

Back to Glioblastoma trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia

Key details

Phase

Early testing / Safety & dosing

Sponsor

Emory University

Collaborators

National Cancer Institute (NCI)

Enrollment target

~24 participants

Started

January 2021

Primary completion

August 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Last updated February 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.